RXST Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
RxSight Inc (RXST) is not a strong buy at the moment for a beginner investor with a long-term strategy. The company's financial performance shows declining revenue, and while there are some improvements in margins and EPS, the overall outlook remains cautious. Analysts are neutral, and there are no significant positive catalysts to suggest immediate upside potential. Additionally, technical indicators and options data do not signal a strong entry point.
The MACD is positive but contracting, RSI is neutral at 31.465, and moving averages are converging, indicating no clear trend. The stock is trading near its support level of 7.655, with resistance at 8.301. Overall, the technical indicators suggest a lack of strong momentum.
The company beat EPS expectations in Q4 2025, and gross margins improved to 77.47%. Analysts have slightly raised price targets, and the stock trades at a discount to peers.
Revenue declined by 18.91% YoY in Q4 2025, and the company projects a cautious 2026 revenue outlook. Operating expenses are expected to remain high, and there is no evidence of significant insider or hedge fund activity. Analyst sentiment remains neutral, and trading trends are stagnant.
In Q4 2025, revenue dropped by 18.91% YoY to $32.6 million, while net income improved to -$9.2 million, up 54.13% YoY. EPS increased to -$0.22, up 46.67% YoY. Gross margin improved to 77.47%, but the company anticipates higher operating expenses in 2026.
Analysts are neutral on RXST. William Blair initiated coverage with a Market Perform rating, citing stalled sales and the need for evidence of a turnaround. Piper Sandler and Morgan Stanley raised price targets slightly to $11 and $10, respectively, but maintain Neutral and Equal Weight ratings.
